Strong RSV Vaccine Results Gives GSK An Edge Over Rival Pfizer

But Competition Will Be Fierce

 
• By Andrew McConaghie

GSK looks to have established an efficacy edge over its rivals in developing a vaccine against the respiratory syncytial virus, but analysts expect early 2023 approvals to spark a closely fought contest.

GSK House, August 2022
Employees at the GSK's HQ in London. Its RSV candidate could be a $2bn blockbuster, and has been boosted by the new efficacy data. • Source: GSK

More from Business

More from Scrip